In vitro and in vivo anti-schistosomal activity of the alkylphospholipid analog edelfosine

dc.contributor.authorYepes, Edward
dc.contributor.authorVarela-M, Rubén E.
dc.contributor.authorLópez-Abán, Julio
dc.contributor.authorHabib Dakir, E. L.
dc.contributor.authorMollinedo, Faustino
dc.contributor.authorMuro, Antonio
dc.date.accessioned2019-08-08T06:01:44Z
dc.date.available2019-08-08T06:01:44Z
dc.date.issued2014
dc.description.abstractSchistosomiasis is a parasitic disease caused by trematodes of the genus Schistosoma. Five species of Schistosoma are known to infect humans, out of which S. haematobium is the most prevalent, causing the chronic parasitic disease schistosomiasis that still represents a major problem of public health in many regions of the world and especially in tropical areas, leading to serious manifestations and mortality in developing countries. Since the 1970s, praziquantel (PZQ) is the drug of choice for the treatment of schistosomiasis, but concerns about relying on a single drug to treat millions of people, and the potential appearance of drug resistance, make identification of alternative schistosomiasis chemotherapies a high priority. Alkylphospholipid analogs (APLs), together with their prototypic molecule edelfosine (EDLF), are a family of synthetic antineoplastic compounds that show additional pharmacological actions, including antiparasitic activities against several protozoan parasites.en_US
dc.identifier.issn1932-6203
dc.identifier.urihttps://repositorio.usc.edu.co:8443/xmlui/handle/123456789/521
dc.language.isoenen_US
dc.publisherPLoS ONEen_US
dc.titleIn vitro and in vivo anti-schistosomal activity of the alkylphospholipid analog edelfosineen_US
dc.typeArticleen_US

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
In Vitro and In Vivo Anti-Schistosomal Activity of the.PDF
Size:
1.27 MB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: